Kala Bio preliminary Q3 2026 net loss narrows about 90% to $800,000
KALA•Kala Bio’s preliminary third-quarter 2026 net loss narrowed approximately 90% year over year to about $800,000. For the nine months ended September 30, its net loss narrowed 86% to approximately $4 million, and it had about $7 million in cash, cash equivalents and short-term investments with no debt.
1. Preliminary results
Kala Bio’s preliminary third-quarter 2026 net loss narrowed approximately 90% year over year to about $800,000. For the nine months ended September 30, 2026, net loss narrowed 86% year over year to approximately $4 million; cash, cash equivalents and short-term investments totaled approximately $7 million, with no debt.
